Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gilead Sciences, Inc. < Previous 1 2 3 4 5 6 7 8 9 Next > Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers March 06, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD MRUS New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19 March 05, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health March 05, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. February 27, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance February 26, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024 February 26, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conferences February 20, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics February 12, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers CBAY GILD Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC February 09, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend February 06, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results February 06, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Ted Love, MD, Joins Gilead Sciences’ Board of Directors February 01, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy January 30, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024 January 23, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Provides Update on Phase 3 EVOKE-01 Study January 22, 2024 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conference December 21, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data December 21, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program December 19, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers CGEN GILD Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas December 11, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers December 11, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma December 11, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year December 11, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023 November 30, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite and Arcellx Announce Expansion in Strategic Partnership November 15, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers ACLX GILD Gilead Sciences to Present at Upcoming Investor Conferences November 08, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Third Quarter 2023 Financial Results November 07, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers November 06, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD RCUS Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023 November 03, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023 November 02, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer October 31, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.